Our Mission
We're building towards a disease-free world. Every patient deserves access to precisely designed therapeutics, and we're creating the AI platform to make that possible.
The Challenge
Traditional therapeutic design is slow, expensive, and limited by human intuition. It takes years and billions of dollars to bring a single drug to market.
Most potential therapeutics never make it past early development due to unforeseen issues with efficacy, safety, or manufacturing.
Our Approach
We combine evolutionary algorithms, protein language models, and AgentFabric™ to explore therapeutic sequence space at unprecedented scale.
Our platform optimizes for multiple objectives simultaneously: potency, safety, stability, and manufacturability, to deliver better candidates faster.
What Drives Us
Scientific Rigor
We pursue the truth with intellectual honesty and reproducible methods.
Patient First
Every decision is guided by our mission to help patients in need.
Bold Innovation
We tackle the hardest problems with creativity and determination.
Leadership Team
Dr. Ivan Garibay
Co-Founder & Founding CEO
Director, Complex Adaptive Systems Laboratory at UCF. Pioneer in evolutionary computation and multi-agent systems.
Dr. Edwin Nassiff
Co-Founder & Founding COO
Former CTO of Enterprise Information Systems at Lockheed Martin Corporation. Former CIO in the US Government.
Dr. Sanjay Padhi
Co-Founder & Founding CTO
Former Head of AWS Research. CTO of Tag.bio. 20+ years AI and cloud. 2025 Breakthrough Prize in Physics (CERN Collaboration).
Our Journey
From foundational research to NeurIPS — the milestones that shaped DeepBio Scientific.
Accepted into NVIDIA Inception Program
Just one week after founding, DeepBio Scientific joins NVIDIA's global startup community defining the future of AI and accelerated computing — unlocking access to cutting-edge GPU infrastructure, technical expertise, and go-to-market support.
About NVIDIA InceptionDeepBio Scientific Founded
Founded by scientists and industry leaders with deep expertise in evolutionary computation, enterprise systems, cloud infrastructure, and biotech commercialization.
Foundation Model Publication
Foundation model research presented at NeurIPS 2025 — one of the world's premier machine learning conferences — establishing DeepBio's scientific credibility in AI-driven therapeutics.
NeurIPS 2025Funded by NSF I-Corps
Awarded NSF I-Corps Regional Team funding — validating the commercial potential of DeepBio's AI-driven drug discovery platform through rigorous customer discovery and market validation.
About NSF I-CorpsUCF AI Drug Discovery Feature
UCF researchers featured in the press for advancing AI-assisted drug discovery — highlighting the potential to dramatically cut the billions of dollars and decades of time traditional drug development demands.
Read the articlePartner With Us
Ready to accelerate your drug discovery pipeline with AI-powered molecular design? Let's discuss how we can help.
Get in Touch